KeyCorp Weighs in on Solventum’s FY2027 Earnings (NYSE:SOLV)

Solventum Corporation (NYSE:SOLV) – Analysts at KeyCorp boosted their FY2027 earnings per share (EPS) estimates for shares of Solventum in a research note issued to investors on Sunday, January 25th. KeyCorp analyst B. Fishbin now expects that the company will post earnings per share of $6.90 for the year, up from their prior forecast of $6.88. KeyCorp has a “Overweight” rating and a $97.00 price target on the stock. The consensus estimate for Solventum’s current full-year earnings is $6.58 per share.

SOLV has been the topic of several other research reports. Mizuho set a $100.00 price objective on Solventum and gave the stock an “outperform” rating in a report on Tuesday, January 20th. BTIG Research upgraded Solventum from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a research report on Tuesday, December 2nd. Wall Street Zen raised shares of Solventum from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Zacks Research cut shares of Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. Finally, Stifel Nicolaus raised their price target on shares of Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Seven analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $90.83.

Solventum Trading Down 1.9%

NYSE:SOLV opened at $77.51 on Tuesday. Solventum has a 1 year low of $60.70 and a 1 year high of $88.20. The stock has a market cap of $13.44 billion, a P/E ratio of 8.93, a P/E/G ratio of 7.23 and a beta of 0.34. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50. The stock has a 50-day simple moving average of $81.72 and a 200-day simple moving average of $75.77.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The firm had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.05 billion. During the same period in the prior year, the firm earned $1.64 earnings per share. The business’s quarterly revenue was up .7% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS.

Solventum declared that its board has authorized a share buyback program on Thursday, November 20th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 7.5% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Institutional Trading of Solventum

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC boosted its stake in Solventum by 0.6% in the 2nd quarter. Nisa Investment Advisors LLC now owns 33,974 shares of the company’s stock worth $2,577,000 after purchasing an additional 210 shares in the last quarter. Chelsea Counsel Co. raised its holdings in Solventum by 720.7% in the 2nd quarter. Chelsea Counsel Co. now owns 10,595 shares of the company’s stock worth $804,000 after purchasing an additional 9,304 shares during the period. South Dakota Investment Council lifted its position in shares of Solventum by 3.6% during the 2nd quarter. South Dakota Investment Council now owns 255,625 shares of the company’s stock valued at $19,387,000 after buying an additional 8,960 shares in the last quarter. Purus Wealth Management LLC purchased a new position in Solventum during the second quarter valued at $252,000. Finally, ST Germain D J Co. Inc. lifted its stake in Solventum by 84.6% in the 2nd quarter. ST Germain D J Co. Inc. now owns 825 shares of the company’s stock valued at $63,000 after buying an additional 378 shares in the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.